相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Frequency of CCR5 genotypes in HIV-infected patients in Roraima, Brazil
Andre de Lima Guerra Corado et al.
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2016)
HIV-1 Entry Cofactor: Functional cDNA Cloing of a Seven-Transmembrane, G protein-Coupled Receptor
Yu Feng et al.
JOURNAL OF IMMUNOLOGY (2011)
HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes
Kosuke Miyauchi et al.
CELL (2009)
A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1
Michael Saag et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Selection of a Simian-Human Immunodeficiency Virus Strain Resistant to a Vaginal Microbicide in Macaques
Dawn M. Dudley et al.
JOURNAL OF VIROLOGY (2009)
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41
Cleo G. Anastassopoulou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Elite Suppressor-Derived HIV-1 Envelope Glycoproteins Exhibit Reduced Entry Efficiency and Kinetics
Kara G. Lassen et al.
PLOS PATHOGENS (2009)
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject
Athe M. N. Tsibris et al.
JOURNAL OF VIROLOGY (2008)
Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection
Gerd Faetkenheuer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120
Robert A. Ogert et al.
VIROLOGY (2008)
Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists
Rama Kondru et al.
MOLECULAR PHARMACOLOGY (2008)
Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity
Michael A. Lobritz et al.
JOURNAL OF VIROLOGY (2007)
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss
Cleo G. Anastassopoulou et al.
PLOS PATHOGENS (2007)
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
Pavel Pugach et al.
VIROLOGY (2007)
Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors
Neelanjana Ray et al.
JOURNAL OF VIROLOGY (2007)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
Structural definition of a conserved neutralization epitope on HIV-1 gp120
Tongqing Zhou et al.
NATURE (2007)
Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652
Masanori Baba et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Genetic protection against hepatitis B virus conferred by CCR5 Delta 32: Evidence that CCR5 contributes to viral persistence
Chloe L. Thio et al.
JOURNAL OF VIROLOGY (2007)
An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry
Diana Safarian et al.
VIROLOGY (2006)
Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients
Beatrice Labrosse et al.
JOURNAL OF VIROLOGY (2006)
Functional impact of HIV coreceptor-binding site mutations
Mark J. Biscone et al.
VIROLOGY (2006)
Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex
Carolina Herrera et al.
VIROLOGY (2006)
Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20)
Xing-Quan Zhang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells
XZ Yang et al.
JOURNAL OF VIROLOGY (2006)
Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-Infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
M Westby et al.
JOURNAL OF VIROLOGY (2006)
Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events
HT Ho et al.
JOURNAL OF VIROLOGY (2006)
CCR5 deficiency increases risk of symptomatic West Nile virus infection
WG Glass et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor
RS Veazey et al.
NATURE MEDICINE (2005)
Structure of a V3-containing HIV-1 gp120 core
CC Huang et al.
SCIENCE (2005)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1
XZ Yang et al.
JOURNAL OF VIROLOGY (2005)
Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion
SR Mkrtchyan et al.
JOURNAL OF VIROLOGY (2005)
Generation and properties of a human immunodeficiency virus type I isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D)
AJ Marozsan et al.
VIROLOGY (2005)
Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry
AJ Marozsan et al.
JOURNAL OF VIROLOGY (2005)
Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization
JD Reeves et al.
JOURNAL OF VIROLOGY (2005)
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus
EJ Platt et al.
JOURNAL OF VIROLOGY (2005)
V3: HIV's switch-hitter
O Hartley et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2005)
Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry
J Daecke et al.
JOURNAL OF VIROLOGY (2005)
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20)
J Lu et al.
JOURNAL OF VIROLOGY (2004)
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor
SE Kuhmann et al.
JOURNAL OF VIROLOGY (2004)
Identification of amino acid residues crucial for chemokine receptor dimerization
P Hernanz-Falcón et al.
NATURE IMMUNOLOGY (2004)
Medicinal chemistry applied to a synthetic protein: Development of highly potent HIV entry inhibitors
O Hartley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies
AA Nabatov et al.
JOURNAL OF VIROLOGY (2004)
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor
CE Baldwin et al.
JOURNAL OF VIROLOGY (2004)
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5
MM Lederman et al.
SCIENCE (2004)
Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity
JD Reeves et al.
JOURNAL OF VIROLOGY (2004)
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection
RS Veazey et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding
PF Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection
FA Koning et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement
B Roscic-Mrkic et al.
BLOOD (2003)
Role of the human immunodeficiency virus type 1 envelope gene in viral fitness
HR Rangel et al.
JOURNAL OF VIROLOGY (2003)
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry
F Tsamis et al.
JOURNAL OF VIROLOGY (2003)
The structural biology of type I viral membrane fusion
PM Colman et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle
C Blanpain et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES
C Pastore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors
B Labrosse et al.
JOURNAL OF VIROLOGY (2003)
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
JD Reeves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors
H Issafras et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor
EG Cormier et al.
JOURNAL OF VIROLOGY (2002)
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
XP Wei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
G protein-coupled receptor allosterism and complexing
A Christopoulos et al.
PHARMACOLOGICAL REVIEWS (2002)
Association of chemokine-mediated block to HIV entry with coreceptor internalization
SM Brandt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies
C Blanpain et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
A Trkola et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
JM Strizki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES
AJ Marozsan et al.
JOURNAL OF VIROLOGY (2001)
Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion
KA Nagashima et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children
L Ometto et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Aminooxypentane addition to the chemokine macrophage inflammatory Protein-1αP increases receptor affinities and HIV inhibition
JR Townson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Endocytosis and recycling of the HIV coreceptor CCR5
N Signoret et al.
JOURNAL OF CELL BIOLOGY (2000)
Maturation of HIV envelope glycoprotein precursors by cellular endoproteases
M Moulard et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON BIOMEMBRANES (2000)
Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion
GB Melikyan et al.
JOURNAL OF CELL BIOLOGY (2000)
A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression
ME Quiñones-Mateu et al.
JOURNAL OF VIROLOGY (2000)
Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans
P An et al.
AIDS (2000)
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
CA Derdeyn et al.
JOURNAL OF VIROLOGY (2000)
Energetics of the HIV gp120-CD4 binding reaction
DG Myszka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1
SE Kuhmann et al.
JOURNAL OF VIROLOGY (2000)
Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120
C Rizzuto et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2000)
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
T Dragic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs
VS Torre et al.
JOURNAL OF VIROLOGY (2000)
分享论文
